Christianna Wood - Delaware Investments Independent Trustee
Insider
Christianna Wood is Independent Trustee of Delaware Investments Minnesota since 2019.
| Age | 60 |
| Tenure | 5 years |
| Phone | 215-255-1200 |
| Web | https://www.delawareinvestments.com/closed-end/products/delaware-investments-minnesota-municipal-income-fund-ii-inc.aspx |
Delaware Investments Management Efficiency
The company has Return on Asset of 1.72 % which means that on every $100 spent on assets, it made $1.72 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 4.4 %, implying that it generated $4.4 on every 100 dollars invested. Delaware Investments' management efficiency ratios could be used to measure how well Delaware Investments manages its routine affairs as well as how well it operates its assets and liabilities.Delaware Investments Minnesota has 75 M in debt with debt to equity (D/E) ratio of 0.43, which is OK given its current industry classification. Delaware Investments has a current ratio of 14.86, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Delaware to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ozlem MD | BioNTech SE | 57 | |
| David Nakasone | Tarsus Pharmaceuticals | N/A | |
| MD MA | Mind Medicine | 44 | |
| Sierk Poetting | BioNTech SE | 51 | |
| Dianne MSW | Tarsus Pharmaceuticals | 47 | |
| CMA CPA | Catalyst Pharmaceuticals | 51 | |
| BS CPA | Inhibrx | 42 | |
| Philip Schwartz | Catalyst Pharmaceuticals | 69 | |
| Preethi Sundaram | Catalyst Pharmaceuticals | 48 | |
| Robert Barrow | Mind Medicine | 35 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Brian JD | Catalyst Pharmaceuticals | 60 | |
| Elizabeth MD | Tarsus Pharmaceuticals | 46 | |
| Wong JD | Mind Medicine | 54 | |
| Ryan Richardson | BioNTech SE | 45 | |
| Gregory Henderson | Analog Devices | 55 | |
| Seshadri Neervannan | Tarsus Pharmaceuticals | 56 | |
| Scott MD | Mind Medicine | 67 | |
| Michael Boehler | BioNTech SE | N/A | |
| Mary Coleman | Catalyst Pharmaceuticals | N/A | |
| Jens Holstein | BioNTech SE | 61 | |
Management Performance
Delaware Investments Leadership Team
Elected by the shareholders, the Delaware Investments' board of directors comprises two types of representatives: Delaware Investments inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Delaware. The board's role is to monitor Delaware Investments' management team and ensure that shareholders' interests are well served. Delaware Investments' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Delaware Investments' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ann Borowiec, Independent Trustee | ||
| Joseph Chow, Independent Director | ||
| Shawn Lytle, President, Chief Executive Officer, Director | ||
| Daniel Geatens, Vice President Treasurer | ||
| Frances SevillaSacasa, Independent Trustee | ||
| Richard Salus, Chief Financial Officer, Senior Vice President | ||
| Janet Yeomans, Independent Director | ||
| Christianna Wood, Independent Trustee | ||
| Lucinda Landreth, Independent Director | ||
| Thomas Bennett, Independent Chairman of the Director | ||
| Jerome Abernathy, Independent Trustee | ||
| John Fry, Independent Director | ||
| Thomas Whitford, Independent Director | ||
| David Connor, Vice President Deputy General Counsel, Secretary |
Delaware Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Delaware Investments a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 4.4 | |||
| Return On Asset | 1.72 | |||
| Profit Margin | 91.47 % | |||
| Operating Margin | 82.79 % | |||
| Current Valuation | 231.35 M | |||
| Shares Outstanding | 11.51 M | |||
| Shares Owned By Institutions | 32.66 % | |||
| Number Of Shares Shorted | 3.79 K | |||
| Price To Earning | 20.37 X | |||
| Price To Book | 0.89 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Delaware Stock
If you are still planning to invest in Delaware Investments check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Delaware Investments' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |